BamSEC and AlphaSense Join Forces
Learn More

Xencor Inc.

NASDAQ: XNCR    
Share price (12/27/24): $24.29    
Market cap (12/27/24): $1.700 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 1 page Executive Employment Letter Addendum #2
12/34/56
EX-10.1
from 10-Q 10 pages Xencor, Inc. Consulting Agreement Effective Date: April 19, 2024
12/34/56
EX-10.4
from 10-Q 3 pages Fourth Amendment to the License Agreement by and Between Xencor, Inc. and Morphosys AG [Remainder of Page Intentionally Left Blank.]
12/34/56
EX-10.3
from 10-Q 4 pages Material contract
12/34/56
EX-10.2
from 10-Q 5 pages Material contract
12/34/56
EX-10.1
from 10-Q 14 pages Third Amendment to Lease
12/34/56
EX-10.47
from 10-K 70 pages Amended and Restated Collaboration and License Agreement by and Between, on the One Hand, Xencor, Inc., And, on the Other Hand, Genentech, Inc. and F. Hoffmann-La Roche Ltd, Effective as of June 1, 2024
12/34/56
EX-10.2
from 10-Q 24 pages Executive Employment Agreement Addendum
12/34/56
EX-10.1
from 10-Q 23 pages Executive Employment Agreement Addendum
12/34/56
EX-10.2
from 8-K 47 pages Certain Confidential Information (Marked by Brackets as “[***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Royalty Purchase Agreement (Monjuvi®/Minjuvi®) Xencor, Inc. as Seller - And - Ocm Life Sciences Portfolio LP as Purchaser November 3, 2023
12/34/56
EX-10.1
from 8-K 51 pages Certain Confidential Information (Marked by Brackets as “[***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Royalty Purchase Agreement Xencor, Inc. as Seller - And - Ocm Life Sciences Portfolio LP as Purchaser November 3, 2023
12/34/56
EX-10.1
from 10-Q 3 pages First Amendment to Collaboration and License Agreement
12/34/56
EX-10.43
from 10-K 4 pages Second Amendment to Option and License Agreement
12/34/56
EX-10.42
from 10-K 3 pages First Amendment to Option and License Agreement Background
12/34/56
EX-10.40
from 10-K 2 pages Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.39
from 10-K 4 pages Sixth Amendment to Lease
12/34/56
EX-10.1
from 10-Q 21 pages Second Amendment to Lease
12/34/56
EX-10.1
from 10-Q 7 pages First Amendment to Office Lease
12/34/56
EX-10.39
from 10-K 160 pages ​ ​ ​ ​ ​ ​ ​ Collaboration and License Agreement by and Between Xencor, Inc. and Janssen Biotech, Inc. ​ Dated October 1, 2021
12/34/56
EX-10.38
from 10-K 2 pages Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56